Phase I study of Ro 31-7453 [R 440; MKC-1], a novel cell cycle inhibitor, administered as escalating oral doses in adults with solid tumors: 4-day schedule
Phase of Trial: Phase I
Latest Information Update: 03 Feb 2010
At a glance
- Drugs MKC 1 (Primary)
- Indications Breast cancer; Colorectal cancer; Lung cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 17 Dec 2009 Actual end date (Aug 2001) added as reported by ClinicalTrials.gov.
- 04 Oct 2005 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History